Avastin-Tarceva combo falls short in trial

A high-powered drug combo didn't make the grade in a new lung cancer trial. Combining Genentech's Avastin and OSI Pharmaceuticals' Tarceva didn't boost survival for patients who had not responded to chemotherapy, failing the trial's primary endpoint. Release | Report

Suggested Articles

Mobile has become universal, accessible, and multi-generational. It’s time for life science brands to revolutionize how they’re telling their story.

Former Retrophin CEO was hoping for a SCOTUS hail mary to escape his seven-year fraud sentences Turns out the court was interest in hearing his plea.

A new investigation shines light on how Purdue pushed back on negative coverage of opioids, placed opioid-friendly experts in think tanks and more.